Loading patent…
AssigneeCrystal Pharmaceutical (Suzhou) Co., Ltd.
InventorsMinhua Chen, Yanfeng Zhang, Xiaoting Zhai, Jing Zhang, Qun Zhang
Estimating the term…
The present invention relates to novel cabozantinib malate crystalline forms, preparation methods for the cabozantinib malate, a pharmaceutical composition comprising the novel cabozantinib malate crystalline forms, and use of the novel cabozantinib malate crystalline forms in the preparation of MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT inhibitors and pharmaceutical preparations for treating cancers such as thyroid cancer, lung cancer, kidney cancer and liver cancer. The cabozantinib malate crystalline forms provided by the present invention has one or more improved properties compared with the prior art, and the preparation method for the cabozantinib malate provided by the present disclosure has a lower cost and better quality of the obtained product compared with the prior art, having important value for future optimization and development of this drug.
A process for preparing crystalline form M2 of Compound I, wherein the process comprises:
A crystalline form CSI of Compound I, wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2 theta values of 8.5°±0.2°, 12.7°±0.2° and 13.9°±0.2° using CuKα radiation.
A crystalline form CSIII of Compound I of Compound I, wherein the X-ray powder diffraction pattern comprises characteristic peaks at 2 theta values of 8.5°±0.2°, 21.3°±0.2°, and 23.0°±0.2° using CuKα radiation.
Dependencies are inferred from the claim text.